Skip to main content
. 2023 Sep 1;12(17):5721. doi: 10.3390/jcm12175721

Figure 2.

Figure 2

The overall trend in peripheral blood eosinophil (PBE) counts for patients after starting dupilumab therapy. PBE counts that could be tracked every 3 months over the follow-up period from 1 April 2019 to 31 October 2022 were indicated (n = 37). Black dotted lines are patients without premedicated biotherapy, red lines are patients premedicated with anti-IL-5/IL-5R antibody, and blue lines are patients premedicated with omalizumab. The horizontal green dotted line indicates a PBE count of 1500 cells/µL, and the vertical green dotted line indicates 6 months.